In one paragraphArticle in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Senamile L NgemaCentre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.ORCID 0000-0003-4355-5068 Saranathan RajagopalanDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.ORCID 0000-0003-2201-8028 Rubeshan PerumalCentre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.
Sashen MoodleyAfrican Health Research Institute, University of KwaZulu-Natal, Durban, South Africa.
Kevin J GuzmanDivision of Pulmonary, Allergy, and Critical Care Medicine, Columbia University Medical Center, New York, New York, USA.
Adrie J C SteynAfrican Health Research Institute, University of KwaZulu-Natal, Durban, South Africa.ORCID 0000-0001-9177-8827 William R JacobsDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
Kogieleum NaidooCentre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.
Max O'DonnellDivision of Pulmonary, Allergy, and Critical Care Medicine, Columbia University Medical Center, New York, New York, USA.
Michelle H LarsenDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.ORCID 0000-0002-3532-350X Funding
Molecular Genetic Analysis of Mycobacterium TuberculosisR37AI026170 · NIAID · ALBERT EINSTEIN COL OF MED YESHIVA UNIV · PI WILLIAM Robert JACOBS · 2004 to 2026
$7.7MNovel Reporter Phages to Detect Complex TB Drug Resistance and PersistenceR01AI114900 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI Michelle H Larsen, Max O'Donnell · 2015 to 2026
$7.2MPromoting Engagement in the Drug Resistant TB/HIV Care Continuum in South AfricaR01AI124413 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI O'DONNELL, MAX, PADAYATCHI, NESRI · 2016 to 2020
$2.7MNanoluciferase reporter phage for rapid phenotypic characterization of resistance to next-generation antimycobacterial agentsR21AI168940 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI JACOBS, WILLIAM ROBERT, O'DONNELL, MAX · 2023 to 2024
$421kNational Research Foundation centre of excellence MND210624615487NIAID NIH HHS R01 AI114900NIAID NIH HHS R01 AI124413NIAID NIH HHS R21 AI168940NIAID NIH HHS R37 AI026170The European & Developing Countries Clinical Trials Partnership (EDCTP) Fellowships TMA2018SF-2467US National Institutes of Health R01AI114900US National Institutes of Health R21AI168940US National Institutes of Health R37AI026170
6 · The paper itselfAbstract
There is an urgent need for rapid, affordable diagnostic tools capable of detecting baseline and treatment-emergent resistance among patients with drug-resistant tuberculosis (DR-TB). Reporter mycobacteriophages provide a phenotypic solution enhanced by brighter luminescent reporters compatible with simple readouts. We applied the TM4:: IMPORTANCE: Ongoing transmission of drug-resistant tuberculosis (DR-TB), combined with limited access to rapid diagnostics for resistance to key drugs in modern regimens, poses a major challenge to global TB control. We applied TM4::
Indexed as
Antitubercular AgentsDiarylquinolinesMycobacteriophagesMycobacterium tuberculosisNitroimidazolesTuberculosis, Multidrug-ResistantGenes, ReporterHumansMicrobial Sensitivity TestsAntitubercular AgentsbedaquilineDiarylquinolinesNitroimidazolespretomanidbedaquilinedelamaniddrug susceptibility testingmycobacteriophagesMycobacterium tuberculosispretomanid
Identifiers
PMID42454942
PMCPMC13436348
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390